[1]杨 莉.TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察[J].医学信息,2018,31(17):17-19.[doi:10.3969/j.issn.1006-1959.2018.17.005]
　YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Journal of Medical Information,2018,31(17):17-19.[doi:10.3969/j.issn.1006-1959.2018.17.005]
点击复制

TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年17期
页码:
17-19
栏目:
出版日期:
2018-09-01

文章信息/Info

Title:
Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma
文章编号:
1006-1959（2018）17-0017-03
作者:
杨 莉
四川省江油市人民医院肿瘤科，四川 江油 621700
Author(s):
YANG Li
Department of Oncology,People's Hospital of Jiangyou,Jiangyou 621700,Sichuan,China
关键词:
非小细胞肺癌; TP方案; 回生口服液
Keywords:
Key words：Non-small cell lung carcinoma; TP regimen; Huisheng oral liquid
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2018.17.005
文献标志码:
A
摘要:
目的 探讨紫杉醇+顺铂化疗方案联合回生口服液治疗中晚期NSCLC的疗效。方法 选取2014年1月~2017年5月于我院就诊的中晚期NSCLC患者68例，随机分为观察组和对照组，每组34例。对照组予以TP方案（紫杉醇+顺铂）治疗，观察组予以TP方案联合回生口服液治疗，对比两组患者的临床疗效、不良反应、血清VEGF、IL-6、MMP-9水平和生存时间、生活质量。结果 观察组的治疗总有效率为70.59%，高于对照组的55.89%，差异具有统计学意义（P＜0.05）。观察组治疗后的VEGF、IL-6、MMP-9水平均低于对照组，差异具有统计学意义（P＜0.05）。观察组治疗后的生活质量评分高于对照组，差异具有统计学意义（P＜0.05）。观察组的肿瘤进展时间为（5.46±2.76）个月、生存时间（11.04±0.82）个月，少于对照组的肿瘤进展时间为（4.15±2.15）个月、生存时间（8.12±0.64）个月（Log Rank: statistic=4.15，P=0.037）。观察组不良反应率为20.59%，低于对照组的41.18%，差异具有统计学意义（P＜0.05）。结论 TP方案联合回生口服液治疗中晚期NSCLC的临床疗效良好，可有效改善中晚期NSCLC患者的炎症状态，抑制肿瘤心血管生成，提高肿瘤细胞杀伤能力，临床疗效显著，安全性高，患者治疗后的生存期有效延长，生活质量明显提高。
Abstract:
Abstract：Objective To investigate the efficacy of paclitaxel+cisplatin chemotherapy combined with Huisheng oral liquid in the treatment of advanced NSCLC.Methods A total of 68 patients with advanced NSCLC who were admitted to our hospital from January 2014 to May 2017 were randomly divided into observation group and control group,with 34 cases in each group.The control group was treated with TP regimen(paclitaxel+cisplatin),and the observation group was treated with TP regimen combined with Huisheng oral liquid.The clinical efficacy,adverse reactions,serum VEGF,IL-6,MMP-9 levels,survival time and quality of life were compared between the two groups.Results The total effective rate of the observation group was 70.59%,which was higher than that of the control group 55.89%,the difference was statistically significant(P<0.05).The levels of VEGF,IL-6 and MMP-9 in the observation group were lower than those in the control group,the difference was statistically significant(P<0.05).The quality of life scores of the observation group after treatment were higher than those of the control group,the difference was statistically significant(P<0.05).The tumor progression time of the observation group was(5.46±2.76)months and survival time(11.04±0.82)months,and the tumor progression time was less than(4.15±2.15)months and survival time(8.12±0.64)month(Log Rank:statistic=4.15,P= 0.037).The adverse reaction rate of the observation group was 20.59%,which was lower than that of the control group 41.18%and the difference was statistically significant(P<0.05).Conclusion TP regimen combined with Huisheng oral liquid is effective in the treatment of advanced NSCLC.It can effectively improve the inflammatory state of patients with advanced NSCLC,inhibit tumor cardiovascular production,improve tumor cell killing ability,clinical efficacy is significant,and safety is high.After treatment the survival period is effectively extended and the quality of life is significantly improved.

参考文献/References:

[1]吴明君,王向东,陈瑜,等.回生口服液联合一线化疗方案对晚期非小细胞肺癌患者血清VEGF,IL-6和MMP-9水平的影响[J].临床与病理杂志,2017,37(12):2605-2610. [2]袁星星.回生口服液联合同步放化疗治疗局部晚期NSCLC的疗效观察[D].安徽医科大学,2017. [3]石织宏,黄织春.参芪散联合TP方案治疗晚期非小细胞肺癌患者的疗效及其对免疫功能的影响[J].世界中医药,2016,11(11):2340-2343,2347. [4]林琪,陈明聪,陈德连,等.TP方案联合芪胶升白胶囊治疗中晚期非小细胞肺癌的疗效观察[J].中国中医药科技,2016,23(03):327-328. [5]桑新文.益气养阴清肺汤联合NP方案治疗老年非小细胞肺癌的临床观察[J].医学信息,2011,24(09):5700-5701. [6]杨学宁,吴一龙.实体瘤治疗疗效评价标准--RECIST[J].循证医学,2004(02):85-90,111. [7]杜军华,尹宜发,乔洪源.回生口服液维持治疗对中晚期非小细胞肺癌生存质量及无进展生存期的影响[J].临床荟萃,2015,30(06):641-644. [8]张晓炜.复方红豆杉胶囊联合TP方案治疗中晚期非小细胞肺癌的疗效观察[J].陕西中医,2015,36(07):833-835. [9]钟媛,张明,兰海涛.艾迪注射液联合TP治疗老年中晚期非小细胞肺癌观察[J].现代临床医学,2017,43(02):120-121,124. [10]魏亚宁,段敏丹,贾友超,等.回生口服液治疗晚期非小细胞肺癌的疗效及对TGF-β,-α表达的影响[J].中国老年学杂志,2014,34(21):6072-6073. [11]田博文.回生口服液联合化疗治疗中晚期小细胞肺癌31例临床疗效观察[J].现代诊断与治疗,2014,25(13):3041-3042. [12]刘华.回生口服液对中晚期非小细胞肺癌辅助治疗临床观察[J].吉林医学,2014,35(19):4295-4296. [13]白广德,黄丁平,陆运鑫,等.中西医结合治疗中晚期非小细胞肺癌的临床研究[J].医学信息,2010,23(08):2567-2569.

相似文献/References:

[1]田 亮,郭 楠,苗志刚,等.非小细胞肺癌中ZEB1和FoxO3a表达及意义[J].医学信息,2018,31(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
　TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(17):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[2]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
　TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(17):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[3]李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的 表达及其临床意义[J].医学信息,2018,31(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
　LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Journal of Medical Information,2018,31(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[4]吴森林,高 斌.中性粒细胞/淋巴细胞比值与介入治疗中晚期非小细胞肺癌患者预后的相关性[J].医学信息,2019,32(03):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
　WU Sen-lin,GAO Bin.Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(17):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
[5]田春琴,赵新汉,蒋冬梅,等.二线用药EGFR-TKIs治疗非选择型NSCLC疗效的Meta分析[J].医学信息,2018,31(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
　TIAN Chun-qin,ZHAO Xin-han,JIANG Dong-mei,et al.Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC[J].Journal of Medical Information,2018,31(17):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
[6]徐闻霞,陆红艳,黄 斌.胸腔镜肺叶切除和肺段切除治疗ⅠA期非小细胞肺癌的疗效比较[J].医学信息,2018,31(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
　XU Wen-xia,LU Hong-yan,HUANG Bin.Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(17):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
[7]付红星,冯小剑,彭文苗,等.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].医学信息,2018,31(24):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
　FU Hong-xing,FENG Xiao-jian,PENG Wen-miao,et al.Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(17):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
[8]阳 芳,黄 斌,覃超群,等.血清KL-6水平与安罗替尼治疗的非小细胞肺癌预后的关系[J].医学信息,2022,35(12):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
　YANG Fang,HUANG Bin,QIN Chao-qun,et al.Relationship Between Serum KL-6 Level and Prognosis of Non-small Cell Lung Cancer Treated with Anlotinib[J].Journal of Medical Information,2022,35(17):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
[9]贾殿军,王利军,程险峰,等.可手术的非小细胞肺癌患者外周静脉血cfDNA总浓度及长片段DNA浓度的临床价值研究[J].医学信息,2019,32(04):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]
　JIA Dian-jun,WANG Li-jun,CHENG Xian-feng,et al.Clinical Value of Total cfDNA Concentration and Long Fragment DNA Concentration in Peripheral Venous Blood of Patients with Operative Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(17):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]
[10]孟凡亮,陈亚新,高建荣,等.血清Ang-2、VEGF、PCDGF在非小细胞肺癌中的诊断价值[J].医学信息,2019,32(15):66.[doi:10.3969/j.issn.1006-1959.2019.15.021]
　MENG Fan-liang,CHEN Ya-xin,GAO Jian-rong,et al.Diagnostic Value of Serum Ang-2,VEGF and PCDGF in Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(17):66.[doi:10.3969/j.issn.1006-1959.2019.15.021]

更新日期/Last Update: 2018-09-01